Comparative Pharmacology
Head-to-head clinical analysis: DOLISHALE versus DURADYNE DHC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOLISHALE versus DURADYNE DHC.
DOLISHALE vs DURADYNE DHC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DOLISHALE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, enhancing serotonin neurotransmission.
DURADYNE DHC contains dihydrocodeine, an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception and response.
Adults: 200 mg orally twice daily or 400 mg orally once daily. Administer with food.
1 tablet (10 mg hydrocodone/300 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
None Documented
None Documented
Terminal elimination half-life: 12 hours (range 10-14) in adults; prolonged in renal impairment (up to 24 hours with CrCl <30 mL/min)
Terminal elimination half-life of dihydrocodeine is approximately 4 hours; clinically relevant for dosing interval of 4-6 hours.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Primarily renal excretion of metabolites; ~90% excreted in urine as glucuronide conjugates and morphine; ~10% in feces via bile.
Category C
Category C
Opioid Analgesic
Opioid Analgesic